U.S. Pharma Stock News

Yuanbao (NasdaqGM:YB) has opened 2026 with Q1 results that put the focus squarely on the income statement, reporting revenue of ¥1,315.9 million and basic EPS of ¥8.60, supported by net income of ¥387.6 million. Over recent quarters the company has seen revenue move from ¥970.1 million in Q1 2025 to ¥1,315.9 million in Q1 2026, while basic EPS shifted from ¥17.87 to ¥8.60 over the same period. This gives investors a clear look at how the top line and per share earnings are evolving together...

Recent performance and context for Nu Holdings Nu Holdings (NYSE:NU) has drawn investor attention after a period of weaker share performance, with the stock down 14% over the past month and 17% over the past 3 months. See our latest analysis for Nu Holdings. That recent weakness sits against a tougher backdrop, with the share price down 31.73% year to date and the 1 year total shareholder return down 8.93%. However, the 3 year total shareholder return of 58.10% shows longer term holders are...

Wondering if SoFi Technologies at around US$15.87 is a bargain or already priced for big expectations? This article focuses squarely on what the current share price implies about value. The stock has been volatile, with the share price down 4.9% over the past week, down 2.4% over the last 30 days, down 42.2% year to date, yet still up 5.4% over the past year and 62.9% over three years, while the five year return sits 27.3% lower. Recent coverage of SoFi Technologies has continued to focus on...

Colgate-Palmolive (NYSE:CL) has appointed Stanley J. Sutula III to its Board of Directors. The appointment expands the board with additional corporate finance, operations, and risk management experience. The move aligns with the company’s focus on global expansion and category leadership across its consumer products portfolio. For you as an investor, this matters because Colgate-Palmolive operates in everyday consumer staples, an area where leadership decisions can influence how capital is...

Carvana (CVNA) has drawn fresh attention after recent trading left the stock down about 12% over the past month but ahead roughly 15% over the past 3 months, inviting a closer look at its drivers. See our latest analysis for Carvana. At a share price of US$67.25, Carvana’s recent swings, including a 1 day share price decline of 3.39% and a 7 day share price return of 5.66%, sit alongside a year to date share price return that is down 15.99% and a 3 year total shareholder return that is very...

Ciena (CIEN) has drawn investor attention after recent trading, with the stock down about 1% over the past day and about 25% over the past month, despite positive annual revenue and net income growth. See our latest analysis for Ciena. The recent 1 day share price decline of 1.07% and 7 day fall of 29.94% sit against a much stronger backdrop, with a 90 day share price return of 29.04% and year to date gain of 76.64%. The 1 year total shareholder return is extremely high, so recent weakness...

e.l.f. Beauty (ELF) is in the spotlight after a busy stretch that combined stronger-than-expected quarterly results, cautious analyst commentary on demand, insider stock sales, and a fresh global expansion push for Rhode. See our latest analysis for e.l.f. Beauty. The recent 1-day share price return of 4.40% and 7-day share price return of 11.79% come after a tougher stretch, with the 90-day share price return down 19.92% and the 1-year total shareholder return down 53.32%. The 5-year total...

Why Barrick Mining stock is drawing attention now Barrick Mining (B) has been under pressure recently, with the stock down 21% over the past month and 16% over the past 3 months. This has prompted investors to reassess its current valuation. See our latest analysis for Barrick Mining. Recent trading has been difficult for Barrick Mining, with the share price falling 5.01% in the last day and 20.87% over the past month. However, the 1 year total shareholder return of 87.94% and 3 year total...

If you are wondering whether Rocket Lab's current share price lines up with its underlying value, it helps to separate the story from the numbers and look at what recent price moves and valuation checks are really saying. The stock closed at US$105.05, with the price down 8.4% over the past week and 10.5% over the past month, yet still up 38.2% year to date and 284.0% over the last year. These moves can shift how investors think about both upside potential and risk. Recent news around the...

Clean Harbors stock snapshot after recent performance Clean Harbors (CLH) has been relatively steady, with the stock roughly flat over the past 3 months and higher over the past year, which may prompt investors to reassess its recent returns. See our latest analysis for Clean Harbors. At a share price of $288.64, Clean Harbors has seen its short term momentum cool slightly over the past month, while its year to date share price return of 18.57% and 1 year total shareholder return of 27.82%...

Wondering if Array Technologies at around US$6.84 is a bargain or a value trap? This article walks through what the current price might be implying. The stock has fallen 21.9% over the past week, 21.7% over the past month, 29.4% year to date, and 12.0% over the past year. This may signal that market expectations and perceived risk around the stock have shifted. Recent coverage has focused on Array Technologies as a solar equipment provider in a sector where investor sentiment can swing...

In early June 2026, Franklin Resources’ Western Asset Management unit agreed to pay a US$100 million civil penalty to settle SEC charges related to alleged cherry-picking by former co-chief investment officer Kenneth Leech, resolving both SEC and Department of Justice investigations. This closure removes a long-running regulatory overhang, allowing Franklin Resources to refocus on its broader asset management franchise, including growth areas such as alternatives, tokenization and ETFs...

Earlier this month, Arcutis Biotherapeutics highlighted ongoing ZORYVE momentum, upcoming regulatory and clinical milestones, and its move to a self-sustaining financial footing, while also supporting new expert guidance on genital psoriasis care published in the American Journal of Clinical Dermatology. The combination of strengthening ZORYVE fundamentals and Arcutis-backed clinical guidance in an under-recognized psoriasis subtype underscores the company’s broader ambitions in high-need...

If you are trying to work out whether Axon Enterprise at around US$447 per share is priced for perfection or still offers value, the next sections walk through what the current numbers actually say. The stock has been volatile recently, with a decline of 7% over the past week and a gain of 13.5% over the past month. It remains down 20.6% year to date and down 42.5% over the last year, while still sitting on a 126.3% gain over three years and 194.5% over five years. Recent coverage has...

Event context and recent performance SLB (SLB) has come into focus for investors after a recent move in its share price, with the stock closing at $55.51 and showing mixed short term performance alongside stronger returns over the past year. See our latest analysis for SLB. Recent trading has been slightly softer, with the 1-day share price return down 0.61% and the 7-day share price return down 2.36%. This sits within a much stronger backdrop that includes a 90-day share price return of...

Two U.S. lawmakers who oversee national security and technology recently disclosed purchases of NasdaqGS:LITE shares. The trades came after Lumentum announced a multi year AI partnership with Nvidia and as its advanced optical technologies expand. The buying activity highlights growing policy level attention on Lumentum's role in U.S. AI and communications infrastructure. Lumentum operates in optical and photonics technologies that sit at the core of data centers, communications networks...

Photronics recently reported second-quarter 2026 results showing broadly flat sales at US$209.94 million year-on-year but significantly higher net income of US$31.43 million, while also issuing third-quarter guidance that points to operating margin pressures and participating in the Bank of America 2026 Global Technology Conference. The earnings release has also prompted a securities-law investigation and sharp criticism from market commentators, highlighting growing scrutiny of how...

In recent days, Centene reported strong Q1 2026 results, raised its full‑year adjusted diluted EPS guidance, and cut its debt by US$1.00 billion, while also earning a place on Bank of America’s US 1 List and renewed support from other major analysts. This combination of better‑than‑planned earnings, balance sheet strengthening, and heightened institutional attention reinforces Centene’s position as a key player in government‑sponsored healthcare and managed care. Now we’ll examine how...

Encompass Health (EHC) is back on investor radars after opening Eastside Rehabilitation Hospital in Loganville, Georgia. The 40 bed facility is a joint venture with Piedmont that expands its inpatient rehabilitation footprint in the state. See our latest analysis for Encompass Health. The recent Georgia hospital opening and new facilities planned in West Virginia come as Encompass Health’s share price, at US$103.35, shows modest momentum, with a 3.04% 90 day share price return but a 12.87%...

Neurocrine Biosciences (NasdaqGS:NBIX) reported new data on INGREZZA showing strong symptom improvements in tardive dyskinesia for patients with intellectual and developmental disabilities. Additional analyses indicated meaningful benefits and remission rates in patients with hepatic impairment, a group that often faces limited dosing options. The findings highlight functional gains and rapid symptom relief in challenging real world populations beyond the broader tardive dyskinesia...

If you are wondering whether NetScout Systems stock still offers value at current levels, it helps to compare its recent performance with what the underlying business could justify. The stock last closed at US$40.30, with returns that include a decline of 4.7% over the past week, a small fall of 0.9% over the past month, and gains of 50.1% year to date and 69.6% over the last 12 months. Recent coverage has focused on NetScout Systems as investors reassess how the company fits into the...

Hims & Hers Health (NYSE:HIMS) has introduced a new monthly Weight Loss Membership that offers more flexible access to GLP-1 treatments and ongoing medical support. The company has completed its acquisition of Eucalyptus, adding operations in markets such as Germany, Australia, and Japan and expanding its telehealth reach. These moves represent a shift in how Hims & Hers approaches weight management and global online care, with potential implications for its customer base and service...

Sociedad Química y Minera de Chile S.A. recently held a board meeting where Hernán Büchi Buc was appointed Vice Chairman and reported first-quarter 2026 results showing sales of US$1,760.11 million and net income of US$364.72 million, both higher than a year earlier. The combination of stronger earnings, higher earnings per share from continuing operations, and increased lithium sales volumes has reinforced the company’s role as a key supplier in a tight lithium market. We’ll now examine how...

In recent days, Insperity reported quarterly results showing 1.7% year-on-year revenue growth that aligned with expectations but missed full-year EPS guidance, while management highlighted ongoing margin pressure. Adding intrigue, Chairman and CEO Paul J. Sarvadi made his largest-ever open-market purchase of Insperity stock, buying about US$7.93 million of shares, underscoring insider conviction amid these operational challenges. We’ll now examine how Insperity’s EPS guidance miss and...